AstraZeneca will invest $50bn in the United States by 2030, including a multi‑billion dollar drug substance facility in Virginia for its weight management and metabolic portfolio...

AstraZeneca reports that baxdrostat at 1mg and 2mg doses significantly reduced mean seated systolic blood pressure at 12 weeks versus placebo in patients with uncontrolled or treatment-resistant hypertension, meeting all primary and secondary endpoints, with a favourable safety profile...

AstraZeneca’s Imfinzi (durvalumab) has been approved in the EU for use alongside chemotherapy before, and as monotherapy after, bladder removal surgery in adults with resectable muscle-invasive bladder cancer...

Datroway approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer..

AstraZeneca's Calquence, combined with venetoclax, has received EU approval for treating untreated chronic lymphocytic leukaemia, showing promising trial results...